Vitamin B12 Blood Test: Serum, Active B12, and MMA — What the Results Mean

Disclaimer: This article is for educational purposes only and does not constitute medical advice. All ranges cited are for informational reference and vary between laboratories and assay methods. Consult a qualified medical practitioner before acting on any blood test result.

Vitamin B12 deficiency is one of the most prevalent nutritional deficiencies globally — and among the most frequently missed. Not because clinicians don't test for it, but because the standard test, serum B12, is a poor marker of functional status. A result sitting inside the reference interval provides false reassurance in a significant proportion of cases. Meanwhile, someone with genuinely adequate tissue B12 may return a low-normal serum result and be unnecessarily supplemented.

Understanding which markers to test, what they measure, and how to interpret them together is what separates a routine B12 check from a meaningful assessment of cobalamin status.

---

Why B12 Matters

Vitamin B12 (cobalamin) is an essential cofactor in two critical enzymatic reactions:

1. Methionine synthase — the methylation pathway

B12 (in its methylcobalamin form) is required for methionine synthase to convert homocysteine to methionine. Methionine feeds into the production of S-adenosylmethionine (SAMe), the universal methyl donor involved in DNA methylation, neurotransmitter synthesis, phospholipid production, and gene expression regulation. When B12 is insufficient, homocysteine accumulates — a measurable downstream signal of B12 (and folate) deficiency.

2. Methylmalonyl-CoA mutase — mitochondrial energy metabolism

B12 (in its adenosylcobalamin form) is required for methylmalonyl-CoA mutase to convert methylmalonyl-CoA to succinyl-CoA, a step in the citric acid cycle. When B12 is functionally deficient, methylmalonyl-CoA accumulates and is converted to methylmalonic acid (MMA) — another measurable downstream marker.

Beyond these enzymatic roles, B12 is essential for:

• Myelin synthesis and maintenance — the protective sheath around nerve fibres; B12 deficiency causes progressive demyelination leading to peripheral neuropathy and subacute combined degeneration of the cord in severe cases
• Neurological development — critical during pregnancy and early life
• Erythropoiesis — B12 deficiency impairs DNA synthesis in developing red blood cells, producing macrocytic (enlarged) red cells that carry less oxygen efficiently

---

The Serum B12 Problem

The standard serum B12 test measures total circulating cobalamin — but not all of it is biologically accessible.

B12 in blood is transported by two carrier proteins:

• Haptocorrin (HC): Binds approximately 70–80% of circulating B12. Haptocorrin-bound B12 is biologically unavailable — cells cannot take it up. Its physiological role is unclear; it may function as a reservoir or scavenger.
• Transcobalamin (TC): Binds approximately 20–30% of circulating B12. This fraction — holotranscobalamin (holoTC) — is the only form taken up by cells via receptor-mediated endocytosis at the transcobalamin receptor. It is the metabolically active fraction.

When you receive a serum B12 result, you are looking at the sum of both fractions. A result of 400 pmol/L may reflect 320 pmol/L bound to haptocorrin (unavailable) and only 80 pmol/L on transcobalamin (available to cells). Conversely, a different person with the same serum B12 of 400 pmol/L may have a different distribution.

This creates two clinically important failure modes:

False reassurance (high serum B12, low active B12): Certain conditions release large amounts of haptocorrin-bound B12 into circulation, elevating total serum B12 without any increase in the active fraction. Liver disease (hepatocytes store B12; injury releases it), myeloproliferative disorders (leukaemia, polycythaemia vera), and solid tumours can all drive serum B12 to very high levels while functional B12 at the cellular level is normal or even deficient. An unexpectedly elevated serum B12 — particularly above 900–1000 pmol/L — warrants investigation of the underlying cause.

False alarm (low-normal serum B12, adequate active B12): Some individuals, particularly those with high haptocorrin levels or altered B12 binding kinetics, may return serum B12 results in the low-normal range (150–250 pmol/L) without any functional deficit. Their holoTC and MMA are normal. Supplementing without checking functional markers in this scenario adds cost without benefit.

Australian laboratory reference range: Serum B12 approximately 148–738 pmol/L (e.g., Healthscope/ptex.au platform); some laboratories use 200–900 pmol/L. Exact values vary by laboratory and immunoassay platform. Results near the lower quartile of the reference range — even if technically "normal" — warrant functional investigation in symptomatic individuals.

---

Holotranscobalamin (Active B12 / HoloTC)

Holotranscobalamin is the metabolically active fraction of serum B12 — the 20–30% bound to transcobalamin that cells can actually use.

Why holoTC is the better early marker:

In the depletion sequence (see below), holoTC falls first — before serum B12 drops and before any functional metabolite accumulates. This makes it a more sensitive marker for identifying early-stage depletion, particularly relevant in populations at risk of progressive deficiency.

Reference ranges:

| Category | Range | |---|---| | Standard laboratory reference | >35–40 pmol/L (lab-dependent) | | Functional practitioner target | >50–60 pmol/L | | Grey zone (borderline) | 25–50 pmol/L | | Likely deficient | <25 pmol/L |

A holoTC below 35 pmol/L should prompt further investigation with MMA regardless of serum B12 result. The grey zone (25–50 pmol/L) is where clinical context, symptoms, and MMA together determine the picture.

Availability in Australia: HoloTC testing is not universally available. It is offered through some Sonic Healthcare-affiliated laboratories on the Abbott ARCHITECT platform. It is more expensive than standard serum B12 and is not routinely Medicare-rebatable in the same way. When ordering, request "holotranscobalamin" or "active B12" specifically — not all laboratory information systems will map a "B12" request to holoTC automatically.

---

Methylmalonic Acid (MMA)

Methylmalonic acid is the most specific functional marker of intracellular B12 deficiency available in routine pathology.

When adenosylcobalamin is insufficient, the enzyme methylmalonyl-CoA mutase cannot function normally. Methylmalonyl-CoA accumulates and is shunted to MMA, which is measurable in both serum and urine.

Why MMA is the gold standard functional marker:

MMA elevation reflects deficiency at the cellular level — inside mitochondria, where the enzyme operates. It can be elevated even when serum B12 appears entirely normal. This makes it the most direct available measure of whether B12-dependent cellular function is actually compromised.

Reference ranges:

| Sample type | Normal range | |---|---| | Serum MMA | <280 nmol/L | | Urine MMA (spot) | <3.6 mmol/mol creatinine (lab-dependent) |

Serum MMA above 280 nmol/L in the context of low or low-normal holoTC is strongly consistent with functional B12 deficiency, regardless of the serum B12 result.

Critical limitation — renal impairment: MMA is renally cleared. Reduced kidney function independently elevates MMA, even in the absence of B12 deficiency. Always interpret serum MMA alongside a creatinine or eGFR result. In anyone with known chronic kidney disease, MMA is unreliable as a standalone B12 marker.

---

Homocysteine as the Downstream Marker

Homocysteine accumulates when the methionine synthase reaction is impaired. Because methionine synthase requires both B12 (methylcobalamin) and folate (5-methyltetrahydrofolate), elevated homocysteine can indicate deficiency of either — or both — nutrients. B6 is also involved in a separate homocysteine transsulfuration pathway.

This makes homocysteine less specific than MMA for identifying B12 deficiency in isolation — you cannot use homocysteine alone to distinguish B12 versus folate versus B6 deficiency. It requires interpretation alongside B12, folate, and MMA results.

Despite this limitation, homocysteine serves important purposes:

• It is a sensitive early functional marker — it rises before clinical symptoms appear
• It carries independent cardiovascular risk — elevated homocysteine (particularly above 15 µmol/L) is associated with atherosclerosis, thrombosis, and stroke risk
• It helps confirm functional deficiency when combined with MMA and holoTC

For a detailed breakdown of homocysteine interpretation and cardiovascular implications, see our article on homocysteine and B-vitamin status. For the broader methylation pathway context, the complete guide to the methylation cycle covers the intersection of B12, folate, and MTHFR in depth.

---

The B12 Depletion Sequence

B12 deficiency does not appear suddenly. It develops over a staged progression — and the stage at which it is identified determines how much damage has occurred and how quickly it can be corrected.

| Stage | What changes | Serum B12 | HoloTC | MMA | Homocysteine | Clinical symptoms | |---|---|---|---|---|---|---| | Stage 1 | Tissue stores beginning to deplete | Normal | Falling | Normal | Normal | None | | Stage 2 | Functional deficiency emerging | Normal | Low | Rising | Normal or rising | Subtle (fatigue, brain fog) | | Stage 3 | Metabolic deficiency established | Falling | Low | Elevated | Elevated | Neurological, mood, cognitive | | Stage 4 | Clinical deficiency | Low | Low | Elevated | Elevated | Macrocytic anaemia, neuropathy, subacute combined degeneration |

The clinical implication: Most supplementation trials and clinical diagnoses happen at Stage 3 or 4 — after functional damage has already been accumulating, sometimes for years. HoloTC and MMA identify Stages 1 and 2, where intervention prevents rather than repairs deficiency.

This is why the standard clinical approach — wait until serum B12 is low or the blood film shows macrocytes — systematically underdiagnoses early deficiency and delays treatment.

---

Who Is at Risk in Australia?

Certain populations have substantially higher rates of functional B12 deficiency:

Vegans and vegetarians: B12 is found almost exclusively in animal products (meat, fish, dairy, eggs). Plant foods contain no bioavailable B12. Without supplementation or fortified foods, vegans will reliably develop deficiency over months to years — typically presenting at Stage 3–4 without earlier screening.

Older adults (60+): Absorbing dietary B12 requires intrinsic factor (IF), a glycoprotein produced by gastric parietal cells, which binds B12 and enables ileal uptake. Atrophic gastritis — extremely common with ageing — reduces both intrinsic factor secretion and gastric acid production, impairing food-bound B12 absorption. Crystalline B12 in supplements is absorbed via passive diffusion and does not require intrinsic factor, making supplementation effective where diet is not.

Metformin users: The TONIC trial and subsequent evidence confirm that metformin reduces B12 absorption in a dose-dependent manner, likely by interfering with calcium-dependent ileal uptake of the B12-IF complex. Annual B12 monitoring is recommended for people on long-term metformin, with increased frequency at higher doses.

Proton pump inhibitor (PPI) users: Long-term acid suppression (12+ months of PPI use) reduces gastric acid, which is needed to cleave food-bound B12 from dietary protein. Absorption of B12 from supplements is unaffected. Risk is dose- and duration-dependent.

Crohn's disease: When Crohn's disease affects the terminal ileum — the anatomical site of B12-IF complex absorption — B12 malabsorption occurs regardless of dietary intake. Risk increases after ileal resection.

Gastric surgery and bariatric patients: Sleeve gastrectomy, gastric bypass, and gastrectomy all reduce intrinsic factor production and/or gastric acid, impairing B12 absorption. Lifelong B12 supplementation (often parenteral in gastrectomy patients) is standard of care.

---

Testing in Australia: Practical Notes

Medicare rebate: B12 testing is Medicare-rebatable when deficiency is clinically suspected. The standard serum B12 is routinely available at all major Australian pathology providers (Sonic, Australian Clinical Labs, Dorevitch, QML, etc.). HoloTC availability varies — confirm with the laboratory before ordering.

Not included in standard panels: B12 is not part of a standard liver function test or metabolic panel. It requires specific ordering, either as a standalone request or as part of a micronutrient or nutritional panel.

Sample timing: Morning fasting collection is preferred — not because B12 is significantly affected by acute food intake, but for consistency and to allow a comprehensive panel (lipids, glucose, iron studies) to be collected simultaneously.

Ordering holoTC: If functional deficiency is the clinical question — particularly in at-risk populations with symptoms but a "normal" serum B12 — request holotranscobalamin specifically. This requires a laboratory that offers the Abbott ARCHITECT HoloTC assay. If not available locally, serum B12 plus MMA provides an adequate functional assessment.

Urine vs serum MMA: Serum MMA is generally preferred in clinical practice for ease of collection and reproducibility. Urine MMA (spot or 24-hour) is used in some nutritional medicine contexts and research settings.

For context on related nutritional biomarkers and how they interact with B12 status, the complete iron panel guide covers the macrocytic versus microcytic distinction that commonly arises when B12 deficiency progresses to anaemia.

Those following nutritional biomarker research across multiple markers can find an overview of available research compounds at nutritional biomarker research.

---

Putting It Together: Interpreting the Panel

| Result pattern | Interpretation | |---|---| | Serum B12 normal, holoTC normal, MMA normal | B12 status adequate | | Serum B12 normal, holoTC low, MMA elevated | Functional B12 deficiency despite normal serum B12 — supplement and recheck | | Serum B12 low, holoTC low, MMA elevated | Clear B12 deficiency at multiple levels | | Serum B12 very high (>900 pmol/L), not supplementing | Investigate secondary cause: liver disease, myeloproliferative disorder, malignancy | | MMA elevated, eGFR reduced | MMA unreliable; interpret holoTC and serum B12 in context; consider renal referral | | Homocysteine elevated, MMA normal | Suggests folate or B6 deficiency rather than B12 — check RBC folate and B6 |

---

Frequently Asked Questions

Can I have B12 deficiency symptoms with a "normal" serum B12? Yes. Neurological symptoms, fatigue, and cognitive changes have been documented in individuals with serum B12 in the normal range but low holoTC and elevated MMA. The functional markers — not serum B12 alone — determine tissue-level adequacy.

Is oral supplementation effective for B12 deficiency? For most causes of deficiency (dietary insufficiency, metformin use, PPI use), high-dose oral B12 (1000–2000 mcg daily) is effective because approximately 1% of any dose is absorbed via passive diffusion, independent of intrinsic factor. In true pernicious anaemia (autoimmune destruction of parietal cells with absent intrinsic factor), intramuscular hydroxocobalamin is traditionally used, though high-dose oral B12 has shown equivalence in some trials.

How long does it take to correct B12 deficiency? Serum B12 and holoTC typically normalise within 4–8 weeks of adequate supplementation. MMA normalises within 3 months. Neurological symptoms improve slowly and may take 6–24 months; resolution is not always complete if deficiency was prolonged.

Should I test B12 if I am already supplementing? Testing serum B12 during high-dose supplementation produces unreliable results — serum B12 will be elevated regardless of functional status. MMA is more useful in this context because it reflects cellular function rather than circulating levels. A washout period before testing (typically 2–4 weeks) gives more interpretable results for serum B12 and holoTC.

What is the difference between cyanocobalamin and methylcobalamin supplements? Both are effective. Cyanocobalamin is converted to active cobalamin forms in the body and has the most evidence in clinical trials. Methylcobalamin is directly active but has more variable absorption data. For individuals with impaired methylation (e.g., MTHFR variants), methylcobalamin or hydroxocobalamin is sometimes preferred by practitioners, though the clinical significance of this distinction remains debated.

---

Summary: B12 Marker Reference Ranges

| Marker | Standard Reference | Functional Target | |---|---|---| | Serum B12 | ~148–738 pmol/L (lab-dependent) | >300–400 pmol/L | | Holotranscobalamin (holoTC) | >35–40 pmol/L | >50–60 pmol/L | | Serum MMA | <280 nmol/L | <200 nmol/L | | Homocysteine | <15 µmol/L (lab-dependent) | <10 µmol/L |

---

This article is for educational purposes only and does not constitute medical advice. Reference ranges vary between laboratories and assay platforms. Consult a qualified medical practitioner for interpretation of your individual results.